The Philippines on 22 December 2015 became the first Asian country to approve the sale of the world's first-ever dengue vaccine, Dengvaxia.
The Philippines’ Food and Drug Administration approved the dengue vaccine for the prevention of disease caused by all four dengue types in individuals from 9 to 45 years old living in endemic areas.
Earlier on 9 December 2015, Dengvaxia, manufactured by French pharmaceutical giant Sanofi, secured its first regulatory approval in Mexico.
Key facts related to Dengvaxia vaccine
• The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved Dengvaxia for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas.
• The COFEPRIS approval of Dengvaxia is based on results from an extensive clinical development program involving over 40000 people of different ages, geographic and epidemiological settings, and ethnic and socio-economic backgrounds living in 15 countries.
• According to a World Health Organization (WHO) report published in late 2014, the vaccine had an average rate of effectiveness of about 60.8 percent in protecting against the four strains of dengue now circulating.
• Sanofi is a French multinational pharmaceutical company headquartered in Paris, France.
• It was founded in 1973 as subsidiary of Elf Aquitaine.
• The company engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market.
Now get latest Current Affairs on mobile, Download # 1 Current Affairs App
Who: The Philippines
When: 22 December 2015